Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?

CARSTEN NIEDER, KRISTIAN S. IMINGEN, BARD MANNSAKER and ROSALBA YOBUTA
Anticancer Research January 2021, 41 (1) 355-358; DOI: https://doi.org/10.21873/anticanres.14783
CARSTEN NIEDER
1Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;
2Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: carsten.nieder@nlsh.no
KRISTIAN S. IMINGEN
1Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;
2Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BARD MANNSAKER
1Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROSALBA YOBUTA
1Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Recent studies suggested that target volume size impacts survival in patients with non-small cell lung cancer (NSCLC) receiving radical radiotherapy. Little is known about the impact of target volume size in palliative radiotherapy or chemoradiotherapy. Therefore, we analyzed the overall survival stratified for clinical and planning target volume (CTV and PTV) size. Patients and Methods: A retrospective study of 77 patients who received palliative (chemo)radiotherapy (at least 30 Gy) for non-metastatic NSCLC, largely stage III was performed. Typical radiation doses were 10-13 fractions of 3 Gy and 15 fractions of 2.8 Gy. Results: Median survival was 12 months (2-year rate 18%). Three prognostic factors emerged in the multivariate analysis. Hospitalization in the last 4 weeks before radiotherapy increased the hazard of death by a factor of 2.8 (p=0.002). Presence of a T1 or 2 tumor decreased the hazard of death by a factor of 0.5 (p=0.03). Concomitant chemoradiotherapy decreased the hazard of death by a factor of 0.4 (p=0.003). Conclusion: Target volume size was not significantly associated with survival, suggesting that large size should not preclude palliative (chemo)radiotherapy as long as normal tissue dose constraints can be met.

Key Words:
  • Radiotherapy
  • non-small cell lung cancer
  • palliative treatment
  • tumor size
  • prognostic factors

Patients with inoperable, locally advanced non-small cell lung cancer (NSCLC) are often treated with combined platinum-based chemotherapy and radiotherapy (radical RCT) (1-5). Due to ineligibility resulting from advanced age, comorbidity or reduced performance status, other options may become the preferred approach, e.g. radical radiotherapy alone, palliative radiotherapy alone or palliative RCT (6-8). Decision-making is tailored to individual patients’ ability to tolerate treatment, as well as motivation and goal of treatment. Different survival prediction tools have been developed, which may stratify patients into distinct prognostic groups (9-11). Such information can be used to support pretreatment assessment. However, prognostic scores are commonly derived from a limited number of baseline variables. Newly emerging prognostic factors should be studied to improve already existing tools. In the context of radical RCT, several studies have suggested that gross tumor volume (GTV) or planning target volume (PTV) predicts overall survival (12-15). These metrics of tumor burden have rarely been studied in the setting of contemporary palliative radiotherapy or RCT. Therefore, we performed a retrospective study addressing the prognostic impact of target volume size in patients who started palliative radiotherapy or RCT at our Institution.

Patients and Methods

A retrospective review of 77 consecutive patients treated with palliative 3-dimensional conformal radiotherapy or RCT between 2009 and 2019 was performed. Inclusion was limited to patients with a prescribed total dose of 30-54 Gy and those without distant metastases (stage II or III). Four patients (5%) failed to complete radiotherapy. An additional exploratory analysis of 57 patients with stage IV NSCLC who received identical treatment was also performed. Patients treated with low-dose radiotherapy, primarily 2 fractions of 8.5 Gy, were excluded from both analyses. All 77 study patients had Eastern Cooperative Oncology Group (ECOG) performance status 0-2. In case of RCT, most patients received the Norwegian CONRAD regime (15 fractions of 2.8 Gy, Carboplatin/Vinorelbine before and during radiotherapy) (16, 17). Treatment plans were calculated with Varian Eclipse TPS® and no intensity-modulated or arc-based techniques were employed. Contouring of the GTV was not mandatory. However, the clinical target volume (CTV) and PTV was contoured in all patients. Therefore, analysis was limited to CTV and PTV. Elective lymph node stations were not included in the CTV. The CTV margin expansion varied, depending on availability of 4-D treatment planning scans allowing for an internal target volume (ITV) concept. In case of ITV contouring, 5 mm were added to create the PTV. Otherwise, the CTV was expanded by 8-10 mm to create the PTV. Positron emission tomography (PET) was available in a minority of patients. The typical approach was computed tomography (CT)-based contouring without 4-D registration of respiratory motion. IBM SPSS v.25 was employed for statistical analyses. The latter included chi-square test and univariate Cox regression for associations between overall survival from the start of radiotherapy and clinical and dosimetric variables. Significant variables, i.e. p≤0.05 in two-sided tests, were then included in multivariate forward conditional Cox regression analysis. Actuarial overall survival was calculated according to the Kaplan-Meier method and the log-rank test was employed for comparison of survival curves. At the time of the analysis, 22 patients were alive (censored observations after a median follow-up of 12.6 months). Date of death was known for all remaining patients.

Results

The baseline characteristics of the study population are shown in Table I. The median age was 72 years, range=47-89 years. The median CTV size was 135 ml, range=10-860 ml (25th percentile 60.5 ml, 50th percentile 135 ml, 75th percentile 261.5 ml). The median PTV size was 402 ml, range=45-1272 ml. Table II shows the results of the survival analyses. Three prognostic factors emerged in the multivariate regression analysis. Having been hospitalized in the last 4 weeks before radiotherapy increased the hazard of death by a factor of 2.8 (p=0.002). Having a T1 or 2 tumor decreased the hazard of death by a factor of 0.5 (p=0.03). Receiving concomitant RCT decreased the hazard of death by a factor of 0.4 (p=0.003). Median survival in this study was 12 months (all 77 patients; 2-year rate 18%). Among four patients who failed to complete radiotherapy, three had been hospitalized in the last 4 weeks before start. In the additional exploratory analysis, target volume size did not predict overall survival in patients with stage IV disease, identical to the result of the main study.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Baseline characteristics before palliative radiotherapy in 77 patients.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Prognostic factors for overall survival in 77 patients.

Discussion

Patients with NSCLC not amenable to radical treatment commonly receive palliative thoracic radiotherapy (6, 7, 18, 19). Heterogeneity between studies has been observed regarding prognostic factors for survival (9, 20). A relevant impact of GTV or PTV size has emerged from the literature on radical radiotherapy (12-15) and therefore, we performed this retrospective study in patients treated palliatively. Typical patients were in their 70s, had stage III disease and received 13 fractions of 3 Gy without chemotherapy or 15 fractions of 2.8 Gy with up to 4 cycles of Carboplatin/Vinorelbine. The concomitant RCT regime emerged as a major factor associated with improved survival. The same was true for the presence of T1-2 disease, but not N stage, CTV and PTV. Finally, a history of previous hospitalization (4 weeks before radiotherapy, any cause) impacted survival. The hospitalization variable might be related to other potential predictors of survival, which were not available in our database, e.g., weight loss, comorbidity and frailty. This would also explain why three of four patients who failed to complete radiotherapy had a history of previous hospitalization. Concomitant RCT for patients without contraindications is also endorsed in a recent American guideline (7).

The main limitations of our study are its retrospective design, group size (or statistical power), lack of GTV data, and heterogeneity regarding PET utilization. PET-assisted treatment planning might have resulted in different CTV contouring and should be considered mandatory in the radical treatment setting (21, 22). However, in elderly patients with comorbidity and limited treatment options, routine PET staging is economically difficult to justify, especially if transportation to an outside PET center is needed like in our healthcare region (23). Given that early palliative interventions may influence the outcomes of care for patients with NSCLC (24), it would be interesting to study this paradigm in a patient population like ours, and not just in patients who receive primary systemic therapy. Fortunately, the radiation treatment strategies continue to evolve and it will be interesting to see whether immune checkpoint inhibitors show added benefit in the palliative, non-metastatic setting (25). Overall, our study suggests that large CTVs should not preclude palliative RCT (or monotherapy) as long as normal tissue dose constraints can be met. Recently, recommendations for esophageal dose were published (17), but the risk of pneumonitis must also be considered.

Footnotes

  • Authors’ Contributions

    CN participated in the design of the study and performed the statistical analysis. KSI collected patient data. CN, KSI, BM and RY conceived the study and drafted the article. All Authors read and approved the final article.

  • Conflicts of Interest

    The Authors declare that they have no conflicts of interest regarding this study.

  • Received November 20, 2020.
  • Revision received December 7, 2020.
  • Accepted December 8, 2020.
  • Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Brown S,
    2. Banfill K,
    3. Aznar MC,
    4. Whitehurst P and
    5. Faivre Finn C
    : The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol 92(1104): 20190524, 2019. PMID: 31535580. DOI: 10.1259/bjr.20190524
    OpenUrlCrossRefPubMed
    1. Baldini E,
    2. Tibaldi C and
    3. Delli Paoli C
    : Chemo-radiotherapy integration in unresectable locally advanced non-small-cell lung cancer: a review. Clin Transl Oncol 22(10): 1681-1686, 2020. PMID: 32128671. DOI: 10.1007/s12094-020-02326-6
    OpenUrlCrossRefPubMed
    1. Nieder C,
    2. Pawinski A and
    3. Andratschke NH
    : Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations. Front Oncol 3: 176, 2013. PMID: 23847765. DOI: 10.3389/fonc.2013.00176
    OpenUrlCrossRefPubMed
    1. Ueda Y,
    2. Suzuki O,
    3. Ohira S,
    4. Yagi M,
    5. Sumida I,
    6. Wada K,
    7. Inui S,
    8. Isono M,
    9. Miyazaki M,
    10. Ogawa K and
    11. Teshima T
    : The promising treatment schedule of concurrent chemoradiotherapy for stage III non-small cell lung cancer: Alternative for conventional fractionation using mathematical analysis. Anticancer Res 40(7): 4095-4104, 2020. PMID: 32620658. DOI: 10.21873/anticanres.14408
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Wada K,
    2. Kishi N,
    3. Kanayama N,
    4. Hirata T,
    5. Morimoto M,
    6. Konishi K,
    7. Imamura F,
    8. Teshima T and
    9. Ogawa K
    : Radiation dose escalation in accelerated hyperfractionated radiotherapy for stage III non-small-cell lung cancer. Anticancer Res 38(10): 5951-5958, 2018. PMID: 30275224. DOI: 10.21873/anticanres.12941
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Jumeau R,
    2. Vilotte F,
    3. Durham AD and
    4. Ozsahin EM
    : Current landscape of palliative radiotherapy for non-small-cell lung cancer. Transl Lung Cancer Res 8(Suppl 2): S192-S201, 2019. PMID: 31673524. DOI: 10.21037/tlcr.2019.08.10
    OpenUrlCrossRefPubMed
  4. ↵
    1. Moeller B,
    2. Balagamwala EH,
    3. Chen A,
    4. Creach KM,
    5. Giaccone G,
    6. Koshy M,
    7. Zaky S and
    8. Rodrigues G
    : Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 8: 245-250, 2018. PMID: 29625898. DOI: 10.1016/j.prro.2018.02.009
    OpenUrlCrossRefPubMed
  5. ↵
    1. Nieder C,
    2. Tollåli T,
    3. Yobuta R,
    4. Reigstad A,
    5. Flatøy LR and
    6. Pawinski A
    : Palliative thoracic radiotherapy for lung cancer: What is the impact of total radiation dose on survival? J Clin Med Res 9(6): 482-487, 2017. PMID: 28496548. DOI: 10.14740/jocmr2980w
    OpenUrlCrossRefPubMed
  6. ↵
    1. Nieder C,
    2. Tollåli T,
    3. Haukland E,
    4. Reigstad A,
    5. Flatøy LR and
    6. Dalhaug A
    : External validation of a prognostic score for patients receiving palliative thoracic radiotherapy for lung cancer. Clin Lung Cancer 18(4): e297-e301, 2017. PMID: 28189593. DOI: 10.1016/j.cllc.2017.01.006
    OpenUrlCrossRefPubMed
    1. Strøm HH,
    2. Bremnes RM,
    3. Sundstrøm SH,
    4. Helbekkmo N and
    5. Aasebø U
    : Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial. J Thorac Oncol 9(6): 825-833, 2014. PMID: 24807158. DOI: 10.1097/JTO.0000000000000184
    OpenUrlCrossRefPubMed
  7. ↵
    1. van Oorschot B,
    2. Assenbrunner B,
    3. Schuler M,
    4. Beckmann G and
    5. Flentje M
    : Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer. Strahlenther Onkol 190(3): 270-275, 2014. PMID: 24413894. DOI: 10.1007/s00066-013-0507-y
    OpenUrlCrossRefPubMed
  8. ↵
    1. Bradley JD,
    2. Ieumwananonthachai N,
    3. Purdy JA,
    4. Wasserman TH,
    5. Lockett MA,
    6. Graham MV and
    7. Perez CA
    : Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52: 49-57, 2002. PMID: 11777621. DOI: 10.1016/s0360-3016(01)01772-2
    OpenUrlCrossRefPubMed
    1. Bradley JD,
    2. Paulus R,
    3. Komaki R,
    4. Masters G,
    5. Blumenschein G,
    6. Schild S,
    7. Bogart J,
    8. Hu C,
    9. Forster K,
    10. Magliocco A,
    11. Kavadi V,
    12. Garces YI,
    13. Narayan S,
    14. Iyengar P,
    15. Robinson C,
    16. Wynn RB,
    17. Koprowski C,
    18. Meng J,
    19. Beitler J,
    20. Gaur R,
    21. Curran W Jr. and
    22. Choy H
    : Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16: 187-199, 2015. PMID: 25601342. DOI: 10.1016/S1470-2045(14)71207-0
    OpenUrlCrossRefPubMed
    1. Kim YH,
    2. Ahn SJ,
    3. Kim YC,
    4. Kim KS,
    5. Oh IJ,
    6. Ban HJ,
    7. Chung WK,
    8. Nam TK,
    9. Yoon MS,
    10. Jeong JU and
    11. Song JY
    : Predictive factors for survival and correlation to toxicity in advanced stage III non-small cell lung cancer patients with concurrent chemoradiation. Jpn J Clin Oncol 46(2): 144-151, 2016. PMID: 26590014. DOI: 10.1093/jjco/hyv174
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ladbury CJ,
    2. Rusthoven CG,
    3. Camidge DR,
    4. Kavanagh BD and
    5. Nath SK
    : Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 105(2): 346-355, 2019. PMID: 31175902. DOI: 10.1016/j.ijrobp.2019.05.064
    OpenUrlCrossRefPubMed
  10. ↵
    1. Strøm HH,
    2. Bremnes RM,
    3. Sundstrøm SH,
    4. Helbekkmo N,
    5. Fløtten O and
    6. Aasebø U
    : Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer 109: 1467-1475, 2013. PMID: 23963145. DOI: 10.1038/bjc.2013.466
    OpenUrlCrossRefPubMed
  11. ↵
    1. Nieder C,
    2. Imingen KS,
    3. Mannsåker B,
    4. Yobuta R and
    5. Haukland E
    : Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer. Radiat Oncol 15(1): 91, 2020. PMID: 32357936. DOI: 10.1186/s13014-020-01550-2
    OpenUrlCrossRefPubMed
  12. ↵
    1. Tataru D,
    2. Spencer K,
    3. Bates A,
    4. Wieczorek A,
    5. Jack RH,
    6. Peake MD,
    7. Lind MJ and
    8. Lüchtenborg M
    : Variation in geographical treatment intensity affects survival of non-small cell lung cancer patients in England. Cancer Epidemiol 57: 13-23, 2018. PMID: 30268078. DOI: 10.1016/j.canep.2018.09.001
    OpenUrlCrossRef
  13. ↵
    1. Støchkel FM,
    2. Schou Nørøxe D,
    3. Nygård L and
    4. Fredberg PG
    : Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while? BMC Palliat Care 17(1): 15, 2018. PMID: 29304789. DOI: 10.1186/s12904-017-0270-4
    OpenUrlCrossRefPubMed
  14. ↵
    1. Angelo K,
    2. Norum J,
    3. Dalhaug A,
    4. Pawinski A,
    5. Aandahl G,
    6. Haukland E,
    7. Engljähringer K and
    8. Nieder C
    : Development and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy. Anticancer Res 34(2): 877-885, 2014. PMID: 24511026.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Brodin NP,
    2. Tomé WA,
    3. Abraham T and
    4. Ohri N
    : 18F-Fluorodeoxyglucose PET in locally advanced non-small cell lung cancer: From predicting outcomes to guiding therapy. PET Clin 15(1): 55-63, 2020. PMID: 31735302. DOI: 10.1016/j.cpet.2019.08.009
    OpenUrlCrossRefPubMed
  16. ↵
    1. Grootjans W,
    2. de Geus-Oei LF and
    3. Bussink J
    : Image-guided adaptive radiotherapy in patients with locally advanced non-small cell lung cancer: the art of PET. Q J Nucl Med Mol Imaging 62(4): 369-384, 2018. PMID: 29869486. DOI: 10.23736/S1824-4785.18.03084-4
    OpenUrlCrossRefPubMed
  17. ↵
    1. Norum J,
    2. Søndergaard U,
    3. Traasdahl E,
    4. Nieder C,
    5. Tollåli G,
    6. Andersen G and
    7. Sundset R
    : PET-CT in the sub-arctic region of Norway 2010-2013. At the edge of what is possible? BMC Med Imaging 15: 36, 2015. PMID: 26316132. DOI: 10.1186/s12880-015-0073-0
    OpenUrlCrossRefPubMed
  18. ↵
    1. Nieder C,
    2. Tollåli T,
    3. Haukland E,
    4. Reigstad A,
    5. Flatøy LR and
    6. Engljähringer K
    : Impact of early palliative interventions on the outcomes of care for patients with non-small cell lung cancer. Support Care Cancer 24(10): 4385-4391, 2016. PMID: 27209479. DOI: 10.1007/s00520-016-3278-z
    OpenUrlCrossRefPubMed
  19. ↵
    1. Fitzgerald K and
    2. Simone CB 2nd.
    : Combining immunotherapy with radiation therapy in non-small cell lung cancer. Thorac Surg Clin 30(2): 221-239, 2020. PMID: 32327181. DOI: 10.1016/j.thorsurg.2020.01.002
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (1)
Anticancer Research
Vol. 41, Issue 1
January 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
13 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?
CARSTEN NIEDER, KRISTIAN S. IMINGEN, BARD MANNSAKER, ROSALBA YOBUTA
Anticancer Research Jan 2021, 41 (1) 355-358; DOI: 10.21873/anticanres.14783

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?
CARSTEN NIEDER, KRISTIAN S. IMINGEN, BARD MANNSAKER, ROSALBA YOBUTA
Anticancer Research Jan 2021, 41 (1) 355-358; DOI: 10.21873/anticanres.14783
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Sex Differences in Presentation, Treatment, and Survival in Patients Receiving Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer
  • Palliative Radiotherapy for Non-metastatic Non-small-cell Lung Cancer: Impact of Blood Test Results on Survival
  • Google Scholar

More in this TOC Section

  • Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
  • End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
  • Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • radiotherapy
  • non-small cell lung cancer
  • palliative treatment
  • tumor size
  • prognostic factors
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire